Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 fold » _ fold (Expand Search), 5 fold (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 fold » _ fold (Expand Search), 5 fold (Expand Search)
-
201
-
202
-
203
-
204
-
205
-
206
Wnt5a expressing tumors demonstrate a decrease in markers of the basal tumor subtype.
Published 2014“…MMTV-Wnt1;MMTV-Wnt5a tumors demonstrated a significant decrease in K6-expressing cells as measured by T-test (* = p<0.05).…”
-
207
Mitochondrial dysfunction is driven by decreased mitochondrial dynamics.
Published 2014“…<p>(A) Sensitivity analysis averaged along the time course for the mitochondrial species in the model by varying the mitochondrial-related kinetic rate constant parameters. …”
-
208
-
209
HRMECs treated with 3-Deazaneplanocin A (DZNep) chemical inhibitor demonstrated increased miR-200b and decreased VEGF expression.
Published 2015“…[NG = 5mM D-glucose, HG = 25mM D-glucose, NG+DMSO = 5mM D-glucose + 0.05% DMSO, HG+DMSO = 25mM D-glucose + 0.05% DMSO, NG+DZNEP = 5mM D-glucose + 5μM DZNep, HG+DZNEP = 25mM + 5μM DZNep; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to β-actin for VEGF and U6 for miR-200b, expressed as a fold change of NG].…”
-
210
Tunicamycin produces a concentration- and time-dependent decrease in cell viability in SH-SY5Y cells concomitant with caspase-3 activation.
Published 2013“…<p>(A) Treatment of SH-SY5Y cells with tunicamycin (0.1–5µM) for 24 h caused a progressive decrease in cell viability as measured by Calcein AM cleavage assay. …”
-
211
Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis
Published 2013“…The relative expression (2<sup>-ΔΔCt</sup> mean ± SEM) of hepatic CYP3A4 mRNA was significantly higher in cirrhotic livers (21.76 ± 2.65 vs. 5.91 ± 1.29, P=2.04E-07) but their levels did not significantly correlate with hepatic CYP3A activity (r=-0.43, P=0.08).…”
-
212
Transaldolase deficiency causes a starvation-like response that decreases animal fat content and rewires lipid metabolism gene expression.
Published 2017“…<b>(H)</b> RNAi knockdown of <i>tald-1</i> does not robustly extend lifespan of BD animals. N2 fed <i>EV(RNAi)</i> (mean 18.2±0.2 days, n = 161), N2 fed <i>tald-1(RNAi)</i> (mean 20.4±0.2 days, n = 151), BD animals developed on <i>EV(RNAi)</i> (mean 20.2±0.2 days, n = 123), BD animals developed on <i>tald-1(RNAi)</i> (mean 21.5±0.3 days, n = 150). …”
-
213
-
214
-
215
Cycloheximide (CHX) treatment decreases production of rRNA transcripts by POLR1 and POLR3.
Published 2019“…<p>(A) DAOY cells were treated with CHX (100 μg/ml) for either 6 or 14 hours; for metabolic RNA labelling, 5-EU was added 2 hours before the sample collection. …”
-
216
OCA alone markedly decreases and combined with Gemcitabine or Cisplatin abrogates growth of iCCA xenografts.
Published 2019“…After 4 weeks, when the tumor size was approximately 100 mm<sup>3</sup> (T<sub>0</sub>) mice were treated with OCA (0.03% w/w, 30 mg/kg) alone or combined with Cisplatin (2.4 mg/Kg in 100 μl) or Gemcitabine (1.05 mg/Kg in 100 μl) for 5 additional weeks. a) Results are expressed as percent increase in tumor volume at different time points. …”
-
217
-
218
-
219
-
220